Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Company Overview

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Key Stats

• Today's Range: $9.52 to $9.89
• 50-Day Range: $9.74 to $16.96
• 52-Week Range: $8.33 to $21.00
• Volume: 490,167 shs
• Average Volume: 1.17 million shs
• Market Capitalization: $1.57 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.67
• Consensus Rating: Moderate Buy

Neumora Therapeutics Stock Analysis - MarketRank™

Neumora Therapeutics scored higher than 36% of companies evaluated by MarketBeat, and ranked 805th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neumora Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neumora Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neumora Therapeutics is -5.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neumora Therapeutics has a P/B Ratio of 4.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.06% of the float of Neumora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neumora Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Neumora Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neumora Therapeutics does not currently pay a dividend.

Dividend Growth

Neumora Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

17.06% of the float of Neumora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neumora Therapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.

Change versus previous month

Short interest in Neumora Therapeutics has recently increased by 4.00%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: -0.07

News Sentiment

Neumora Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Neumora Therapeutics this week, compared to 3 articles on an average week.

Search Interest

Only 3 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,059,104.00 in company stock.

Percentage Held by Insiders

26.40% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NMRA Stock Analysis - Frequently Asked Questions

How have NMRA shares performed this year?

Neumora Therapeutics' stock was trading at $17.05 at the start of the year. Since then, NMRA stock has decreased by 42.9% and is now trading at $9.74.
View the best growth stocks for 2024 here.

How were Neumora Therapeutics' earnings last quarter?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by $0.06.

When did Neumora Therapeutics IPO?

Neumora Therapeutics (NMRA) raised $250 million in an initial public offering on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

Who are Neumora Therapeutics' major shareholders?

Neumora Therapeutics' top institutional shareholders include FMR LLC (4.84%), Geode Capital Management LLC (1.23%), State Street Corp (1.11%) and Charles Schwab Investment Management Inc. (0.44%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Kristina Burow, Robert A Lenz and Joshua Pinto.
View institutional ownership trends.

How do I buy shares of Neumora Therapeutics?

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Neumora Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/23/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:NMRA
• CUSIP: N/A
• CIK: 1885522
• Web: neumoratx.com
• Phone: 857-760-0900
• Fax: N/A
• Employees: 108
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.67
• High Stock Price Target: $30.00
• Low Stock Price Target: $13.00
• Potential Upside/Downside: +122.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-235,930,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.63%
• Return on Assets: -68.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.98
• Quick Ratio: 10.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.99 per share
• Price / Book: 4.89

Miscellaneous

• Outstanding Shares: 161,560,000
• Free Float: 118,909,000
• Market Cap: $1.57 billion
• Optionable: Optionable
• Beta: 3.92